Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study

被引：6

作者：

Stoliaroff-Pepin, Anna ^{[1
]}

Peine, Caroline ^{[1
]}

Herath, Tim ^{[1
]}

Lachmann, Johannes ^{[1
]}

Hellenbrand, Wiebke ^{[1
]}

Perriat, Delphine ^{[1
]}

Doerre, Achim ^{[2
]}

Nitsche, Andreas ^{[3
,4
]}

Michel, Janine ^{[3
,4
]}

Grossegesse, Marica ^{[3
,4
]}

Hofmann, Natalie ^{[3
,4
]}

Rinner, Thomas ^{[3
,4
]}

Kohl, Claudia ^{[3
,4
]}

Brinkmann, Annika ^{[3
,4
]}

Meyer, Tanja ^{[5
]}

Stern, Daniel ^{[5
]}

Treindl, Fridolin ^{[5
]}

Dorner, Brigitte G. ^{[5
]}

Hein, Sascha ^{[6
]}

Werel, Laura ^{[6
]}

Hildt, Eberhard ^{[6
]}

Glaeser, Sven ^{[7
]}

Schuehlen, Helmut ^{[8
]}

Isner, Caroline ^{[9
]}

Peric, Alexander ^{[10
]}

Ghouzi, Ammar ^{[11
]}

Reichardt, Annette ^{[12
]}

Janneck, Matthias ^{[13
]}

Lock, Guntram ^{[14
]}

Huster, Dominik ^{[15
]}

Gruenewald, Thomas ^{[16
]}

Schaade, Lars ^{[17
]}

Wichmann, Ole ^{[1
]}

Harder, Thomas ^{[1
]}

机构：

[1] Robert Koch Inst, Dept Infect Dis Epidemiol, Immunizat Unit, Berlin, Germany

[2] Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, Germany

[3] Robert Koch Inst, Ctr Biol Threats & Special Pathogens, WHO Reference Lab SARS CoV 2, ZBS1 Highly Pathogen Viruses, Berlin, Germany

[4] Robert Koch Inst, WHO Collaborating Ctr Emerging Infect & Biol Thre, ZBS1 Highly Pathogen Viruses, Berlin, Germany

[5] Robert Koch Inst, Ctr Biol Threats & Special Pathogens, ZBS3 Biol Toxins, Berlin, Germany

[6] Paul Ehrlich Inst, Div Virol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany

[7] Vivantes Klinikum Neukolln & Spandau, Klin Innere Med Pneumol & Infektiol, Berlin, Germany

[8] Vivantes Netzwerk Gesundheit GmbH, Direktorat Klin Forsch & Akad Lehre, Berlin, Germany

[9] Vivantes Auguste Viktoria Klinikum, Klin Innere Med Infektiol, Rubensstr 125, D-12157 Berlin, Germany

[10] Vivantes Klinikum Friedrichshain, Klin Pneumol & Infektiol, Landsberger Allee 49, D-10249 Berlin, Germany

[11] Schon Klin Dusseldorf, Interdisziplinare Notaufnahme, Heerdter Krankenhaus 2, D-40549 Dusseldorf, Germany

[12] Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, D-13125 Berlin, Germany

[13] Albertinen Krankenhaus, Klin Kardiol, Sekt Nephrol, Suntelstr 11a, D-22457 Hamburg, Germany

[14] Albertinen Krankenhaus, Klin Innere Med, Suntelstr 11a, D-22457 Hamburg, Germany

[15] Helios Klinikum Erfurt, Klin Innere Med, Erfurt, Germany

[16] Klinikum Chemnitz, Klin Infekt & Tropenmed, Chemnitz, Germany

[17] Robert Koch Inst, Ctr Biol Threats & Special Pathogens, Berlin, Germany

来源：

INFECTION | 2023年 / 51卷 / 04期

关键词：

COVID-19; Vaccine effectiveness; Hospitalization; Case-control study; SARS-CoV-2; Omicron;

D O I：

10.1007/s15010-023-02012-z

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

PurposeCOViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave.MethodsWe analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates.Results21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12-78%), 81.5% (95% CI: 68-90%) and 95.6% (95%CI: 88-99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses.ConclusionThree vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.

引用

页码：1093 / 1102

页数：10

共 50 条

[21] Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance
Shkoda, Andrey S.
Gushchin, Vladimir A.
Ogarkova, Darya A.
Stavitskaya, Svetlana, V
Orlova, Olga E.
Kuznetsova, Nadezhda A.
Keruntu, Elena N.
Pochtovyi, Andrei A.
Pukhov, Alexander, V
Kleymenov, Denis A.
Krzhanovsky, Vasyli G.
Vasina, Daria V.
Shkuratova, Nataliya, V
Shidlovskaya, Elena, V
Gorbunov, Alexey L.
Kustova, Daria D.
Mazurina, Evgeniya A.
Kozlova, Sofya R.
Soboleva, Alexandra, V
Grigoriev, Igor, V
Pankratyeva, Lyudmila L.
Odintsova, Alina S.
Belyaeva, Elizaveta D.
Bessonova, Arina A.
Vasilchenko, Lyudmila A.
Lupu, Igor P.
Adgamov, Ruslan R.
Tkachuk, Artem P.
Tokarskaya, Elizaveta A.
Logunov, Denis Y.
Gintsburg, Alexander L.
[J]. VACCINES, 2022, 10 (06)
[22] Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand
Intawong, Kannikar
Chariyalertsak, Suwat
Chalom, Kittipan
Wonghirundecha, Thanachol
Kowatcharakul, Woravut
Thongprachum, Aksara
Chotirosniramit, Narain
Noppakun, Kajohnsak
Khwanngern, Krit
Teacharak, Worachet
Piamanant, Prapon
Chantaklang, Pannawich
Khammawan, Pimpinan
[J]. PLOS ONE, 2023, 18 (05):
[23] Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study
Tang, Lin
Zhang, Yanyang
Wang, Fuzhen
Wu, Dan
Qian, Zhao-Hui
Zhang, Rui
Wang, Ai-Bin
Huang, Chang
Wang, Haifeng
Ye, Ying
Lu, Mingxia
Wang, Changshuang
Ma, Ya-Ting
Pan, Jingjing
Li, Ya-fei
Lv, Xiao-Ya
An, Zhijie
Rodewald, Lance
Wang, Xuan-Yi
Shao, Yi-Ming
Wu, Zhi-Yin
Yin, Zundong
[J]. BMJ OPEN, 2022, 12 (11):
[24] Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization
Feikin, Daniel R.
Higdon, Melissa M.
Andrews, Nick
Collie, Shirley
Knoll, Maria Deloria
Kwong, Jeffrey C.
Link-Gelles, Ruth
Pilishvili, Tamara
Patel, Minal K.
[J]. VACCINE, 2023, 41 (14) : 2329 - 2338
[25] mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
Hung Fu Tseng
Bradley K. Ackerson
Lina S. Sy
Julia E. Tubert
Yi Luo
Sijia Qiu
Gina S. Lee
Katia J. Bruxvoort
Jennifer H. Ku
Ana Florea
Harpreet S. Takhar
Radha Bathala
Cindy Ke Zhou
Daina B. Esposito
Morgan A. Marks
Evan J. Anderson
Carla A. Talarico
Lei Qian
[J]. Nature Communications, 14
[26] mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
Tseng, Hung Fu
Ackerson, Bradley K.
Sy, Lina S.
Tubert, Julia E.
Luo, Yi
Qiu, Sijia
Lee, Gina S.
Bruxvoort, Katia J.
Ku, Jennifer H.
Florea, Ana
Takhar, Harpreet S.
Bathala, Radha
Zhou, Cindy Ke
Esposito, Daina B.
Marks, Morgan A.
Anderson, Evan J.
Talarico, Carla A.
Qian, Lei
[J]. NATURE COMMUNICATIONS, 2023, 14 (01)
[27] Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study
Kim, Yoo-Yeon
Choe, Young June
Kim, Jia
Kim, Ryu Kyung
Jang, Eun Jung
Lee, Hyeryeon
Yi, Seonju
Lee, Sangwon
Park, Young-Joon
[J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (11)
[28] COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England Comment
Kirsebom, Freja C. M.
Andrews, Nick
Stowe, Julia
Toffa, Samuel
Sachdeva, Ruchira
Gallagher, Eileen
Groves, Natalie
O'Connell, Anne-Marie
Chand, Meera
Ramsay, Mary
Bernal, Jamie Lopez
[J]. LANCET INFECTIOUS DISEASES, 2022, 22 (07): : 931 - 933
[29] Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization
Feikin, Daniel R.
Abu-Raddad, Laith J.
Andrews, Nick
Davies, Mary-Ann
Higdon, Melissa M.
Orenstein, Walter A.
Patel, Minal K.
[J]. VACCINE, 2022, 40 (26) : 3516 - 3527
[30] Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak
Ye, Wenjing
Li, Kangguo
Zhao, Zeyu
Wu, Shenggen
Qu, Huimin
Guo, Yichao
Abudunaibi, Buasiyamu
Chen, Wu
Cai, Shaojian
Chen, Cailin
Lin, Jiawei
Xie, Zhonghang
Zhan, Meirong
Ou, Jianming
Deng, Yanqin
Chen, Tianmu
Zheng, Kuicheng
[J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11

← 1 2 3 4 5 →